FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Seehra Jasbir				2. Issuer Name and Ticker or Trading Symbol Keros Therapeutics, Inc. [ KROS ]						(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner						
(Last) (First) (Middle) C/O KEROS THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/07/2020						below)	give title nief Execu	Other (specify below)		oecify		
99 HAYDEN AVENUE, SUITE 120, BUILDING E																	
(Street)	GTON M	1A	02421	4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable le)  X Form filed by One Reporting Person  Form filed by More than One Reporting					
(City)	(5	State)	(Zip)									Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				. Transacti Date Month/Day	Execution Date,		Code (Instr.			5. Amoun Securities Beneficia Owned Fo	s Form ally (D) o ollowing (I) (In		Direct Indirect Etr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) o (D)	r Price	Transaction (Instr. 3 a	on(s)			Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	re Conversion Date Execution Date, Tr or Exercise (Month/Day/Year) if any		Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Employee Stock Option (right to buy)	\$16	04/07/2020		A		696,569		(1)	04	4/06/2030	Common Stock	696,569	\$0.00	696,569	9	D	

## **Explanation of Responses:**

1. One-fourth (1/4th) of the shares subject to the option shall vest on March 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

## Remarks:

/s/ Keith Regnante, Attorney-in-04/08/2020

**Fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.